Wall Street analysts forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will post ($0.25) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dynavax Technologies’ earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.18). Dynavax Technologies posted earnings of ($0.66) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 62.1%. The business is scheduled to announce its next earnings report on Wednesday, August 5th.
According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.00) to ($0.96). For the next fiscal year, analysts forecast that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.67) to ($0.12). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, March 11th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.11). Dynavax Technologies had a negative net margin of 310.97% and a negative return on equity of 722.75%. The business had revenue of $10.57 million for the quarter, compared to analyst estimates of $11.92 million.
DVAX stock traded down $0.74 during midday trading on Tuesday, reaching $7.18. 16,919,309 shares of the company’s stock traded hands, compared to its average volume of 3,256,393. The company has a 50-day simple moving average of $4.28 and a two-hundred day simple moving average of $4.85. Dynavax Technologies has a 1-year low of $1.80 and a 1-year high of $8.12. The company has a market cap of $679.27 million, a price-to-earnings ratio of -4.00 and a beta of 1.14. The company has a quick ratio of 4.99, a current ratio of 6.63 and a debt-to-equity ratio of 18.31.
In related news, Director Andrew A. F. Hack purchased 1,000,000 shares of Dynavax Technologies stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average cost of $4.84 per share, for a total transaction of $4,840,000.00. Also, SVP Robert Janssen sold 15,000 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $6.33, for a total value of $94,950.00. Following the completion of the transaction, the senior vice president now owns 177,266 shares in the company, valued at $1,122,093.78. The disclosure for this sale can be found here. 13.33% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the company. NumerixS Investment Technologies Inc bought a new position in shares of Dynavax Technologies in the 4th quarter worth $41,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Dynavax Technologies by 176.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,318 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 5,311 shares during the last quarter. Panagora Asset Management Inc. bought a new position in shares of Dynavax Technologies in the 4th quarter worth $53,000. ProShare Advisors LLC bought a new position in shares of Dynavax Technologies in the 4th quarter worth $65,000. Finally, Quantitative Investment Management LLC bought a new position in shares of Dynavax Technologies in the 1st quarter worth $46,000. Institutional investors and hedge funds own 67.05% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Recommended Story: What is the Shanghai Stock Exchange Composite Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.